With Chinese biotechs developing therapies at unprecedented speed, a Western startup's primary defense is carefully managing its intellectual property. This requires being highly strategic about when to file patents, what to publish, and what to share publicly, as any information can be rapidly replicated by fast-moving global competitors.
Founders of platform technologies are often tempted to pursue many applications at once. A more effective strategy is to select and aggressively advance a single "beachhead program" to the clinic. This demonstrates the platform's value concretely, making it easier to attract funding and partners, while avoiding the dilution of resources.
Novartis advanced Gleevec, a CML drug, despite a low $200M peak sales forecast because of its "outsized efficacy." This focus on patient impact over financial models led to a $7B blockbuster, proving that transformative clinical results can create their own market and override initial commercial doubts.
A direct path to venture capital in biotech is less effective than one that includes deep operational experience. Gaining experience in research, business development, commercial, and startup C-suite roles provides the credibility and understanding to "speak eye to eye" with portfolio companies and become a much better investor.
The US biotech ecosystem thrives because failure is viewed as a valuable learning experience. In contrast, European culture often penalizes entrepreneurs from failed startups, creating a more risk-averse environment that stifles innovation and limits the pool of experienced operators who are willing to try again.
A critical mindset shift from academia to startups is embracing the "killer experiment." Academics may fear an experiment that disproves a long-held hypothesis. In contrast, biotech startups, with finite capital, must run these experiments early to either validate or kill a program, efficiently allocating resources to viable projects.
Many biotech operators incorrectly define strategy as simply "making the pipeline successful." This is a description of execution. True strategy is the disciplined process of identifying your unique selling point—a scientific advantage no one else has. All tactical plans must flow from this core defensible position.
The Multiple Myeloma Research Foundation (MMRF) started its venture fund because traditional innovation in the field was lagging. By defining priority areas (e.g., in vivo CAR-T) and investing in startups, the fund successfully de-risked the space, demonstrating how philanthropy can bridge critical funding gaps and advance entire fields.